At Ascentage Pharma, we are dedicated to developing innovative therapies that can change the lives of patients with cancer, hepatitis B and age-related diseases. We have built a robust pipeline of eight clinical drug candidates, and are conducting 20 clinical trials in China, the United States and Australia. Our apoptosis-targeted drug candidates are intended to treat cancer and other diseases by restoring the normal function of key apoptotic pathways. We are also developing several next generation tyrosine kinase inhibitors (TKIs) to treat diseases with high unmet medical needs. We are developing these compounds for use as a single agent or in combination with other therapies.